Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132045 | 0.94 | MGLL (0.51) | MGLLCYP3A4CYP2C9RBP4CCR2 | |
| SCHEMBL2131757 | 0.93 | MGLL (0.44) | MGLLCYP3A4CYP2C9RBP4CCR2 | |
| SCHEMBL2131736 | 0.92 | CYP3A4 (0.40) | MGLLCYP3A4CYP2C9RBP4CCR2 | |
| SCHEMBL2733853 | 0.92 | CYP3A4 (0.40) | MGLLCYP3A4CYP2C9RBP4CCR2 | |
| SCHEMBL2131629 | 0.91 | CYP3A4 (0.48) | MGLLCYP3A4CYP2C9RBP4ALDH1A1 | |
| SCHEMBL2130096 | 0.87 | CYP3A4 (0.40) | MGLLCYP3A4CYP2C9RBP4CCR2 | |
| SCHEMBL2131985 | 0.86 | CYP3A4 (0.43) | CYP3A4CYP2C9RBP4CCR2MCHR1 | |
| SCHEMBL2131810 | 0.85 | CYP3A4 (0.47) | MGLLCYP3A4CYP2C9RBP4CCR2 | |
| SCHEMBL2133340 | 0.85 | MGLL (0.45) | MGLLCYP3A4CCR2MCHR1ALDH1A1 | |
| SCHEMBL2131995 | 0.85 | ALDH1A1 (0.40) | MGLLCYP3A4CYP2C9RBP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | claimed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | claimed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | claimed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | claimed |
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | disclosed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | MGLL 3/4885CYP3A4 2393/4885CYP2C9 592/4885 |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | MGLL 3/4885CYP3A4 2393/4885CYP2C9 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.